BioIVT deployed IDBS E-WorkBook, reducing study times by at least 30%

WOKING, England, March 13, 2025 /PRNewswire/ — BioIVT, a leading provider of in vitro ADME research services, has successfully completed a collaboration with IDBS to implement the IDBS E-WorkBook platform, significantly reducing study times by at least 30%. The project has enabled BioIVT to enhance efficiency and responsiveness to its biopharmaceutical clients.

BioIVT sought a technological solution to enhance efficiency and maintain its reputation for responsiveness. The solution needed robust data processing and reporting capabilities to reduce study cycle times and increase capacity. Flexibility and user-friendliness were essential to promote adoption across multiple departments.

After evaluating various options, BioIVT selected the E-WorkBook for its comprehensive capabilities. IDBS worked closely with BioIVT to develop and implement the system, ensuring it met the critical needs of each department. Custom workflows were created to streamline processes and enhance efficiency.

The implementation of E-WorkBook led to significant process improvements across multiple departments. Efficiency gains of 40 to 70% were noted in activities such as documentation, data processing and addressing audit findings. The study director and maintenance and metrology teams experienced the most notable impact, with an overall reduction in time across all activities by at least 30%. This resulted in a 20% increase in capacity, equivalent to weekly time savings of approximately eight hours per user.

“Implementing the IDBS E-WorkBook platform has been transformative for our operations. The streamlined processes and increased efficiency have allowed us to deliver data to our clients at least four weeks faster. This collaboration with IDBS has truly enabled us to achieve our goals,” said Joanna Barbara, PhD, Kansas City Site Lead at BioIVT.

The full case study is available here.

Visit idbs.com, to learn more about IDBS.

About IDBS

IDBS helps BioPharma organizations unlock the potential of AI/ML to improve the lives of patients. As a trusted long-term partner to 80% of the top 20 global BioPharma companies1, IDBS delivers powerful cloud software and services specifically designed to meet the evolving needs of the BioPharma sector.

IDBS, a Danaher company, leverages 35 years of scientific informatics expertise to help organizations design, execute and orchestrate processes, manage, contextualize and structure data and gain valuable insights throughout the product lifecycle, from R&D through manufacturing. Known for its signature IDBS E-WorkBook software, IDBS has extended its flexible, scalable solutions to the IDBS Polar and PIMS cloud platforms to help scientists make smarter decisions with assured confidence in both GxP and non-GxP environments. 

1 Rank measured by Market Cap, Q1 2024.

Learn more at idbs.com.

About BioIVT

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®. For more information, please visit bioivt.com or follow us on LinkedIn.

MEDIA ENQUIRIES

 e |  mediaenquiries@idbs.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bioivt-deployed-idbs-e-workbook-reducing-study-times-by-at-least-30-302401193.html

SOURCE IDBS

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.